Skip to main content

Investigational New Drugs

Ausgabe 2/2018

Inhalt (20 Artikel)

Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition

  • PRECLINICAL STUDIES

Mohammad Mehdi Amiri, Forough Golsaz-Shirazi, Tahereh Soltantoyeh, Reza Hosseini-Ghatar, Tannaz Bahadori, Jalal Khoshnoodi, Shadi Sadat Navabi, Samira Farid, Mohammad Hossein Karimi-Jafari, Mahmood Jeddi-Tehrani, Fazel Shokri

Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer

  • PRECLINICAL STUDIES

Sang Eun Park, Ha-Gyeong Kim, Dong Eun Kim, Yoo Jung Jung, Yunlim Kim, Seong-Yun Jeong, Eun Kyung Choi, Jung Jin Hwang, Choung-Soo Kim

4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma

  • PRECLINICAL STUDIES

Arpita De, Blake A. Jacobson, Mark S. Peterson, Joe Jay-Dixon, Marian G. Kratzke, Ahad A. Sadiq, Manish R. Patel, Robert A. Kratzke

First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile

  • PHASE I STUDIES

Giovanna Speranza, Larry Anderson, Alice P. Chen, Khanh Do, Michelle Eugeni, Marcie Weil, Larry Rubinstein, Eva Majerova, Jerry Collins, Yvonne Horneffer, Lamin Juwara, Jennifer Zlott, Rachel Bishop, Barbara A. Conley, Howard Streicher, Joseph Tomaszewski, James H. Doroshow, Shivaani Kummar

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies

  • Open Access
  • PHASE I STUDIES

Xiaofei Zhou, John Nemunaitis, Shubham Pant, Todd M. Bauer, Manish Patel, John Sarantopoulos, A. Craig Lockhart, Daniel Goodman, Dirk Huebner, Diane R. Mould, Karthik Venkatakrishnan

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies

  • Open Access
  • PHASE I STUDIES

Xiaofei Zhou, Shubham Pant, John Nemunaitis, A. Craig Lockhart, Gerald Falchook, Todd M. Bauer, Manish Patel, John Sarantopoulos, Michael Bargfrede, Andreas Muehler, Lakshmi Rangachari, Bin Zhang, Karthik Venkatakrishnan

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study

  • PHASE I STUDIES

Yutaka Fujiwara, Naoya Yamazaki, Yoshio Kiyohara, Shusuke Yoshikawa, Noboru Yamamoto, Arata Tsutsumida, Hiroshi Nokihara, Kenjiro Namikawa, Akihira Mukaiyama, Fanghong Zhang, Tomohide Tamura

Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies

  • PHASE I STUDIES

Meiqi Shi, Jing Sun, Jinsong Zhou, Hao Yu, Shaorong Yu, Guohao Xia, Li Wang, Yue Teng, Gangyi Liu, Chen Yu, Jifeng Feng, Yaling Shen

A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer

  • PHASE II STUDIES

Evan Y. Yu, Susan L. Ellard, Sebastien J. Hotte, Joel R. Gingerich, Anthony M. Joshua, Martin E. Gleave, Kim N. Chi

A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer

  • PHASE II STUDIES

Muhammad Alamgeer, D. Neil Watkins, Ilia Banakh, Beena Kumar, Daniel J. Gough, Ben Markman, Vinod Ganju

A phase II study of tipifarnib and gemcitabine in metastatic breast cancer

  • PHASE II STUDIES

Clinton Yam, Rashmi K. Murthy, Vicente Valero, Janio Szklaruk, Girish S. Shroff, Carol J. Stalzer, Aman U. Buzdar, James L. Murray, Wei Yang, Gabriel N. Hortobagyi, Stacy L. Moulder, Banu Arun

The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis

  • PHASE III STUDIES

Yuan-Hung Kuo, I-Pei Wu, Jing-Houng Wang, Chao-Hung Hung, Kun-Ming Rau, Chien-Hung Chen, Kwong-Ming Kee, Tsung-Hui Hu, Sheng-Nan Lu

Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer

  • PHASE III STUDIES

Xuenong Ouyang, Meiqi Shi, Fangwei Jie, Yuxian Bai, Peng Shen, Zhuang Yu, Xiuwen Wang, Cheng Huang, Min Tao, Zhehai Wang, Conghua Xie, Qi Wu, Yongqian Shu, Baohui Han, Fengchun Zhang, Yiping Zhang, Chunhong Hu, Xitao Ma, Yongjie Liang, Anlan Wang, Bing Lu, Yi Shi, Jinfei Chen, Zhixiang Zhuang, Jiejun Wang, Jianjin Huang, Changhui Wang, Chunxue Bai, Xin Zhou, Qiang Li, Feng Chen, Hao Yu, Jifeng Feng

Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas

  • SHORT REPORT

Franciele Cristina Kipper, Andrew Oliveira Silva, André Luis Marc, Gláucia Confortin, Augusto Valadão Junqueira, Eliseu Paglioli Neto, Guido Lenz

Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment

  • SHORT REPORT

Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Eiichiro Suzuki, Takahiro Maeda, Masayuki Yokoyama, Toru Wakamatsu, Masanori Inoue, Tomoko Saito, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Shingo Nakamoto, Shin Yasui, Akinobu Tawada, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Osamu Yokosuka, Naoya Kato

Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy

  • SHORT REPORT

Francesco Pasqualetti, Alessandra Gonnelli, Martina Cantarella, Durim Delishaj, Alessandro Molinari, Valerio Ortenzi, Francesco Carbone, Sabrina Montrone, Stefano Ursino, Sara Franceschi, Riccardo Morganti, Paola Orlandi, Teresa Di Desidero, Chiara Maria Mazzanti, Katia Zavaglia, Antonio Giuseppe Naccarato, Guido Bocci, Fabiola Paiar

Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature

  • Open Access
  • SHORT REPORT

Shoichi Deguchi, Koichi Mitsuya, Yoko Nakasu, Nakamasa Hayashi, Hirohisa Katagiri, Hideki Murata, Junji Wasa, Mitsuru Takahashi, Masahiro Endo

Neu im Fachgebiet Onkologie

Kopf-Hals-Tumoren: Die Immuntherapie ist kein Selbstläufer

Ergebnisse einer weiteren Studie legen nahe: Mit einer adjuvanten Immuncheckpointhemmung ist lokal fortgeschrittenen Plattenepithelkarzinomen des Kopf-Hals-Bereichs nur schwer beizukommen. Einige Fachleute geben die Hoffnung jedoch nicht auf und diskutieren mögliche Gründe für die negativen Ergebnisse.

Dänische Zwillingsstudie deutet auf erhöhtes Krebsrisiko bei Tätowierten hin

Haben Tattoo-Träger und -Trägerinnen ein erhöhtes Risiko, an Hautkrebs oder einem Lymphom zu erkranken? Die Ergebnisse einer Zwillingsstudie aus Dänemark scheinen dafür zu sprechen. Die Forschungsgruppe rät vorerst zur Zurückhaltung beim Tätowieren.

Weniger PSA-Screening, mehr fortgeschrittene Tumoren

Eine Empfehlung gegen das Prostatakrebs-Screening, die mehrere Jahre in den Leitlinien des Royal Australasian College of General Practitioners gegeben wurde, hat sich nicht nur auf die Rate von PSA-Tests negativ ausgewirkt.

Schützt kutane Autoimmunität vor Hauttumoren?

Schwedische Registerdaten deuten auf ein geringeres Risiko für bestimmte Hauttumoren bei Personen mit Vitiligo oder autoimmuner Alopezie. Wie es dazu kommt, ist dagegen unklar.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.